miércoles, 11 de enero de 2017

View Clinical Trial NCT02810418 - National Cancer Institute

View Clinical Trial NCT02810418 - National Cancer Institute
National Cancer Institute banner

LMB-100 and Nab-Paclitaxel in Treating Patients with Recurrent, Metastatic, and/or Locally Advanced Pancreatic Cancer

This phase I/II trial studies the side effects and best dose of LMB-100 and paclitaxel albumin-stabilized nanoparticle formulation in treating patients with pancreatic cancer that has come back and has spread to other places in the body. Immunotoxins, such as LMB-100, are antibodies linked to a toxic substance and may help find tumor cells that express the mesothelin protein and kill them without harming normal cells. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving LMB-100 therapy with paclitaxel albumin-stabilized nanoparticle formulation may work in treating patients with pancreatic cancer.
Eligibility Criteria
Locations & Contacts
Trial Objectives and Outline
Trial Phase & Type
Lead Organization
Trial IDs

No hay comentarios:

Publicar un comentario